Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ)
CNY 2.86
(-1.72%)
CNY 2.86
(-1.72%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -219.49 Million CNY | -1692.87% |
| 2022 | 13.77 Million CNY | 101.68% |
| 2021 | -818.54 Million CNY | -459.41% |
| 2020 | 227.74 Million CNY | 23.67% |
| 2019 | 184.16 Million CNY | -47.18% |
| 2018 | 348.66 Million CNY | -40.82% |
| 2017 | 589.19 Million CNY | -28.58% |
| 2016 | 824.98 Million CNY | 30.86% |
| 2015 | 630.42 Million CNY | 90.78% |
| 2014 | 330.45 Million CNY | 47.35% |
| 2013 | 224.26 Million CNY | 25.71% |
| 2012 | 178.4 Million CNY | 31.58% |
| 2011 | 135.57 Million CNY | 73.89% |
| 2010 | 77.96 Million CNY | 202.31% |
| 2009 | 25.78 Million CNY | 91.14% |
| 2008 | 13.49 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -32.03 Million CNY | -394.0% |
| 2024 Q1 | -11.84 Million CNY | 94.98% |
| 2024 Q2 | 10.89 Million CNY | 192.01% |
| 2023 Q2 | 29.67 Million CNY | 56.88% |
| 2023 Q1 | 18.91 Million CNY | 159.61% |
| 2023 Q3 | -12.77 Million CNY | -143.06% |
| 2023 Q4 | -235.78 Million CNY | -1745.03% |
| 2023 FY | -219.49 Million CNY | -1692.87% |
| 2022 Q3 | 5.11 Million CNY | -73.38% |
| 2022 Q1 | 21.16 Million CNY | 102.1% |
| 2022 FY | 13.77 Million CNY | 101.68% |
| 2022 Q4 | -31.73 Million CNY | -719.91% |
| 2022 Q2 | 19.23 Million CNY | -9.12% |
| 2021 FY | -818.54 Million CNY | -459.41% |
| 2021 Q4 | -1 Billion CNY | -1534.98% |
| 2021 Q2 | 52.99 Million CNY | -21.64% |
| 2021 Q3 | 70.35 Million CNY | 32.76% |
| 2021 Q1 | 67.63 Million CNY | 156.54% |
| 2020 FY | 227.74 Million CNY | 23.67% |
| 2020 Q1 | 28.63 Million CNY | 383.85% |
| 2020 Q2 | 46.04 Million CNY | 60.79% |
| 2020 Q3 | 126.69 Million CNY | 175.14% |
| 2020 Q4 | 26.36 Million CNY | -79.19% |
| 2019 Q3 | 43.83 Million CNY | -13.12% |
| 2019 Q4 | -10.08 Million CNY | -123.02% |
| 2019 Q2 | 50.45 Million CNY | -49.52% |
| 2019 Q1 | 99.95 Million CNY | 8297.66% |
| 2019 FY | 184.16 Million CNY | -47.18% |
| 2018 Q2 | 137.1 Million CNY | 22.19% |
| 2018 Q4 | -1.21 Million CNY | -101.21% |
| 2018 FY | 348.66 Million CNY | -40.82% |
| 2018 Q1 | 112.2 Million CNY | 549.34% |
| 2018 Q3 | 100.57 Million CNY | -26.64% |
| 2017 Q2 | 211.3 Million CNY | -1.73% |
| 2017 FY | 589.19 Million CNY | -28.58% |
| 2017 Q3 | 145.59 Million CNY | -31.1% |
| 2017 Q4 | 17.28 Million CNY | -88.13% |
| 2017 Q1 | 215.01 Million CNY | 180.87% |
| 2016 FY | 824.98 Million CNY | 30.86% |
| 2016 Q3 | 206.45 Million CNY | -46.17% |
| 2016 Q2 | 383.52 Million CNY | 142.04% |
| 2016 Q4 | 76.55 Million CNY | -62.92% |
| 2016 Q1 | 158.45 Million CNY | -8.15% |
| 2015 Q1 | 95.76 Million CNY | -10.17% |
| 2015 Q4 | 172.51 Million CNY | 14.86% |
| 2015 Q3 | 150.19 Million CNY | -29.14% |
| 2015 Q2 | 211.96 Million CNY | 121.35% |
| 2015 FY | 630.42 Million CNY | 90.78% |
| 2014 Q2 | 90.78 Million CNY | 33.32% |
| 2014 Q3 | 64.97 Million CNY | -28.42% |
| 2014 Q4 | 106.6 Million CNY | 64.07% |
| 2014 FY | 330.45 Million CNY | 47.35% |
| 2014 Q1 | 68.09 Million CNY | -13.23% |
| 2013 Q2 | 55.29 Million CNY | 42.15% |
| 2013 Q3 | 51.59 Million CNY | -6.7% |
| 2013 Q4 | 78.47 Million CNY | 52.1% |
| 2013 FY | 224.26 Million CNY | 25.71% |
| 2013 Q1 | 38.9 Million CNY | -7.78% |
| 2012 Q3 | 41.26 Million CNY | -24.55% |
| 2012 Q2 | 54.69 Million CNY | 35.89% |
| 2012 FY | 178.4 Million CNY | 31.58% |
| 2012 Q1 | 40.25 Million CNY | 14.48% |
| 2012 Q4 | 42.18 Million CNY | 2.22% |
| 2011 Q1 | 18.89 Million CNY | -50.56% |
| 2011 Q2 | 50.37 Million CNY | 166.56% |
| 2011 Q4 | 35.16 Million CNY | 12.89% |
| 2011 Q3 | 31.14 Million CNY | -38.17% |
| 2011 FY | 135.57 Million CNY | 73.89% |
| 2010 FY | 77.96 Million CNY | 202.31% |
| 2010 Q4 | 38.22 Million CNY | 93.72% |
| 2010 Q3 | 19.73 Million CNY | 0.0% |
| 2009 FY | 25.78 Million CNY | 91.14% |
| 2008 FY | 13.49 Million CNY | 0.0% |